An arsenal of promising new medications, vaccines, and diagnostic tests are moving toward the global battlefield that pits medicine against drug-resistant tuberculosis (TB), which is claiming a terrible toll, particularly in HIV-infected individuals, according to an article scheduled for the Sept. 24 issue of Chemical & Engineering News, ACS’ weekly newsmagazine.